Table 3.

APS phenotypes correlation with aPLs and aPLs profiles

APS phenotypes	Associated aPLs and clinical manifestations	O.R.
Arterial thrombosis	> 7 any aPLsa	4.1 [CI 95% 1.9–96]
	aPT IgG	2.3 [CI 95% 1.1–5.1]
	Primary APS	2.2 [CI 95% 1.1–4.5]
CNS manifestations	aPT + aPG + aPI and aAN (IgG)	2.6 [CI 95% 1.1–6.3]
Venous thrombosis	aP-acid IgM	0.3 [CI 95% 0.1–0.9]
Event free period > 3 years from last thrombotic events	aPI IgG	3 [CI 95% 1.08–8.1]
	aAN IgG	3.4 [CI 95%1.08–10.9]
Pregnancy morbidity	aCL IgG and aPS IgG	2.9 [CI 95% 1.3–6.5]
	anti-AN IgG	2.8 [CI 95% 1.02–8]
	Arterial thrombosis	3.3 [CI 95% 1.5–7.2]
	CNS manifestations	3.9 [CI 95% 1.7–9]
	Secondary APS	2.3 [CI 95%1.03–5.16]

Data is compared among APS patients with and without the defining phenotype

^aCL cardiolipin, β2GP1 beta2-glycoprotein1, P-acid phosphatidic acid, PC phosphatidylcholine, PE phosphatidylethanolamine, PG phosphatidylglycerol, PI phosphatidylinositol, AN annexin 5, PS phosphatidylserine, PT prothrombin